An in vivo study of non-small cell lung carcinoma (NSCLC) showed that downregulation of LOXL2 accelerated disease progression and, when examining tumours from patients, higher stage disease was correlated with low LOXL2 expression [105]. The gene discussed is LOXL2; the disease is neoplasm.